Could RO7851624, newly into clinical trials, be RG6735?
ApexOnco Front Page
Recent articles
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
The group is expanding its mRNA-4359 trial to include first-line melanoma.
FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.
The group scraps cobolimab, alongside MAbs against PVRIG and CD96.
The second-line Litespark-011 and adjuvant Litespark-022 trials are apparently hits.
The company discontinues its Yap/TEAD inhibitor IAG933 owing to lack of tolerability and efficacy.
